KTTA

Pasithea Therapeutics Corp. (KTTA) - Q3 2025 10-Q Summary

Business Context and Reporting Period

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) disorders, RASopathies, and MAPK pathway-driven tumors. The reporting period covers the three and nine months ended September 30, 2025. The Company is classified as a Smaller Reporting Company and an Emerging Growth Company.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: For the nine months ended September 30, 2025, total operating expenses decreased by approximately 3.5% compared to the prior year. Research and Development (R&D) expenses decreased by 7.9% ($452,158), primarily due to the de-prioritization of discovery programs (PAS-003 and PAS-001) and reduced preclinical costs. This was partially offset by a $2.2 million increase in clinical trial expenses for the lead candidate PAS-004.
• General and Administrative (G&A): G&A expenses increased slightly by 1.2% ($62,879) year-to-date, driven by higher accounting, business development, and personnel costs, partially offset by a significant decrease in stock-based compensation.
• Other Income: Other income, net, increased significantly due to a favorable change in the fair value of warrant liabilities ($115,301 gain YTD 2025 vs. $79,212 loss YTD 2024).
• Capital Structure: The Company raised significant capital in the first nine months of 2025 through a May 2025 Public Offering (approx. $4.2 million net proceeds), At-The-Market (ATM) sales (approx. $2.0 million net proceeds), and warrant exercises (approx. $1.3 million).

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: As of September 30, 2025, the Company held approximately $4.1 million in cash. Management explicitly states there is "substantial doubt" about the Company's ability to continue as a going concern for twelve months from the filing date without obtaining additional funding. The Company is dependent on equity or debt financing to continue operations.
• Clinical Progress: The Company is advancing its lead candidate, PAS-004 (a MEK inhibitor). It is conducting a Phase 1 Dose Escalation Study (expected completion in 2026) and initiated a Phase 1/1b trial for Neurofibromatosis Type 1 (NF1) in May 2025. Enrollment for the first cohort of the NF1 trial was completed in July 2025.
• Strategic Shifts: The Company has de-prioritized discovery programs for ALS (PAS-003) and schizophrenia (PAS-001) to focus resources on PAS-004.
• Risks: Key risks include the need for additional capital, the uncertainty of clinical trial outcomes, regulatory approval risks, and the potential impact of inflation on operating costs. The Company is also subject to "baby shelf" rules limiting the amount of equity it can sell via shelf registration due to its public float being under $75 million.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $4.1 million cash balance against the projected burn rate for the ongoing Phase 1 trials of PAS-004.
• Financing Plans: Review management's specific plans for raising additional capital given the "substantial doubt" disclosure and the limitations imposed by the "baby shelf" rules.
• Clinical Milestones: Monitor upcoming data readouts from the PAS-004 Phase 1 Dose Escalation Study and the NF1 Phase 1/1b trial, as these are critical for future valuation and funding.
• Warrant Liability: Note the volatility in net income driven by the fair value changes of warrant liabilities, which are non-cash items but impact reported earnings.
• De-prioritization Impact: Assess the long-term strategic implications of halting the ALS and schizophrenia discovery programs.